Your session is about to expire
← Back to Search
Study Summary
This trial is studying a new treatment called RLS-0071 for adults with moderate exacerbations of COPD, which is a serious lung condition that can cause hospitalization and even death. Exacerb
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has RLS-0071 received the official endorsement of the FDA?
"Our team at Power rates the safety of RLS-0071 as a 2 on a scale from 1 to 3, given that this trial is in Phase 2. This means that there is some available data supporting its safety but no evidence yet regarding efficacy."
What is the current number of participants being recruited for this research endeavor?
"Indeed, the data provided on clinicaltrials.gov confirms that this trial is actively seeking suitable candidates. The initial posting of the study was made on January 1st, 2024, and it has been updated most recently on January 9th, 2024. This clinical trial aims to enroll a total of 24 patients at a single location."
Are patients currently eligible to participate in this ongoing medical study?
"Indeed, as stated on clinicaltrials.gov, this study is currently seeking eligible participants. The trial was initially posted on January 1st, 2024 and underwent its most recent update on January 9th, 2024."
Share this study with friends
Copy Link
Messenger